17 September, 2017
Among 2 analysts covering Livanova Plc (NDAQ:LIVN), 1 have Buy rating, 0 Sell and 1 Hold. The stock has "Hold" rating by Needham on Wednesday, August 23.
08/15/2017 - LivaNova PLC was downgraded to "sell" by analysts at WBB Securities. They now have a $83.00 target on shares. and their target would suggest a possible upside of 21.93 % over the current stock price. Exane Derivatives now owns 3,156 shares of the company's stock valued at $158,000 after buying an additional 2,811 shares in the last quarter. Jefferies initiated it with "Buy" rating and $76 target in Friday, September 8 report.
A number of other institutional investors have also added to or reduced their stakes in the business. Glen Harbor Capital Management LLC lifted its stake in shares of LivaNova PLC by 11.4% in the first quarter. The value of the investment in LivaNova PLC - Ordinary Shares increased from $3,146,000 to $6,293,000 increasing 100.0% quarter over quarter.
Piper Jaffray began new coverage on LivaNova PLC giving the company a "overweight" rating. PNC Financial Services Group Inc. now owns 1,707 shares of the company's stock worth $105,000 after acquiring an additional 153 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of LivaNova PLC by 91.8% in the second quarter. Finally, Texas Permanent School Fund raised its stake in shares of LivaNova PLC by 0.8% in the second quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company's stock valued at $108,000 after buying an additional 763 shares in the last quarter. Glen Harbor Capital Management LLC now owns 2,992 shares of the company's stock valued at $147,000 after buying an additional 306 shares in the last quarter. Arizona State Retirement System raised its stake in shares of LivaNova PLC by 1.7% in the second quarter. Institutional investors and hedge funds own 82.36% of the company's stock. The short-interest ratio increased to 5.0 and the percentage of shorted shares is 0.05% as of August 15. 809K shares changed hands by the end of trading on Friday. LivaNova PLC has a 52-week low of $40.83 and a 52-week high of $69.29. Shares of the company are trading at $68.07 just above $62.35, the stock's 50 day moving average and which is quite a bit above the 200 day moving average of $57.45. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.82 by $0.19. The company had revenue of $321.40 million during the quarter, compared to analysts' expectations of $315.75 million.
11/03/2016 - LivaNova PLC had its "hold" rating reiterated by analysts at Canaccord Genuity. On average, analysts expect that LivaNova PLC will post $3.24 EPS for the current year.
Equity analyst Needham started coverage by announcing an initial rating of "Hold".
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 15th.
Hosking Partners Llp grew its ownership by buying 3,048 shares an increase of 1.6% in the quarter. The Director now owns $3,473,697 of the stock according to the SEC filing.
ILLEGAL ACTIVITY WARNING: "SG Americas Securities LLC Has $1.16 Million Position in LivaNova PLC (LIVN)" was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of U.S. and global copyright & trademark laws.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. It operates in three segments: Neuromodulation, Cardiac Surgery, and Cardiac Rhythm Management. The Cardiac Surgery segment develops, produces, and sells cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical valve replacements, and fix products for damaged or diseased heart valves primarily for perfusionists and cardiac surgeons.